IBRX
Immunitybio Inc
9.30$
+9.9%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 50.4% | – | – | – | -6,617.0% | 20,958.1% | 1,511.9% | – | 10,080.0% | 2,976.2% | 119.1% | 0.7% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 6,717.0% | -20,858.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.3% | |
| 248.8% | 4,844.9% | 60,331.8% | 88,395.6% | 113,655.3% | 113,686.0% | 23,059.0% | 20,980.5% | 103,395.4% | 37,357.9% | 1,289.5% | 183.5% | |
| 674.9% | 96,473.7% | 216,797.7% | 126,935.6% | 60,412.8% | 42,011.6% | 4,504.8% | 14,481.4% | 42,795.0% | 19,730.7% | 1,144.7% | 132.4% | |
| 923.7% | 100,694.9% | 274,856.8% | 207,997.8% | 189,108.5% | 134,739.5% | 36,609.1% | 35,461.9% | 146,474.2% | 58,339.5% | 2,434.2% | 325.3% | |
| -969.1% | -101,218.6% | -282,954.5% | -220,266.7% | -209,338.3% | -155,597.7% | -36,509.1% | -35,361.9% | -146,374.2% | -58,239.5% | -2,334.2% | -226.0% | |
| 0.0% | 0.0% | 150.0% | 1,373.3% | 921.3% | 13,767.4% | 1,499.8% | 1,589.8% | 19,643.8% | 13,941.6% | 892.9% | 99.3% | |
| -969.1% | -100,498.7% | -275,865.9% | -215,368.9% | -205,806.4% | -153,223.3% | -37,360.8% | -37,456.0% | -173,869.2% | -93,873.3% | -2,805.3% | -310.4% | |
| 0.2% | -127.5% | -1,300.0% | -1,095.6% | -1,070.2% | -225.6% | -305.1% | 1.0% | 14.2% | -6.4% | 0.5% | -0.1% | |
| -969.3% | -100,371.2% | -274,565.9% | -214,273.3% | -204,736.2% | -152,997.7% | -36,669.6% | -37,129.6% | -173,569.6% | -93,761.4% | -2,804.8% | -310.2% | |
| -885.6% | -99,875.0% | -267,518.2% | -201,626.7% | -184,555.3% | -132,220.9% | -33,755.4% | -34,341.8% | -146,617.1% | -76,955.5% | -1,793.4% | -197.3% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.